Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.
Transforming growth factor-beta (TGF beta) is produced by most cultured cells in an inactive form. Potential activation mechanisms of latent TGF beta were studied using fibroblastic (NRK-49F and AKR-MCA) cell-conditioned medium as a model. Active TGF beta was monitored by radioreceptor and soft agar assays as well as by antibody inhibition and immunoprecipitation. Little or no TGF beta was detected in untreated conditioned medium. Treatment of the medium with extremes of pH (1.5 or 12) resulted in significant activation of TGF beta as shown by radioreceptor assays, while mild acid treatment (pH 4.5) yielded only 20-30% of the competition achieved by pH 1.5. In an effort to define more physiological means of TGF beta activation, the effects of some proteases were tested. Plasmin and cathepsin D were found to generate 25-kD bands corresponding to the active form of TGF beta as shown by immunoprecipitation analysis of radiolabeled cell-conditioned medium. Plasmin treatment of the medium resulted in activity that was quantitatively similar to that of mild acid treatment as measured by radioreceptor and soft agar assays. In addition, the plasmin-generated activity was inhibited by anti-TGF beta antibodies. Sequential treatments of AKR-MCA cell-conditioned medium with mild acid followed by plasmin or plasmin followed by mild acid gave activation comparable to either treatment alone. The data suggest that conditioned medium may contain at least two different pools of latent TGF beta. One pool is resistant to mild acid and/or plasmin and requires strong acid or alkali treatment for activation. A second pool is activated by mild pH change and/or plasmin. Activation of this form of latent TGF beta may take place by dissociation or proteolytic digestion from a precursor molecule or hypothetical TGF beta-binding protein complex.
Lyons
R M
RM
Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
Keski-Oja
J
J
Moses
H L
HL
D000818:Animals; D000906:Antibodies / Q000276:immunology; D002402:Cathepsin D / Q000494:pharmacology; D002460:Cell Line; D002461:Cell Line, Transformed; D003470:Culture Media; D004305:Dose-Response Relationship, Drug; D005341:Fibrinolysin / Q000494:pharmacology; D005347:Fibroblasts; D006133:Growth Substances / Q000276:immunology / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration; D007118:Immunoassay; D010447:Peptide Hydrolases / Q000494:pharmacology*; D010455:Peptides / Q000276:immunology / Q000378:metabolism*; D015291:Transforming Growth Factors
D000906:Antibodies; D003470:Culture Media; D006133:Growth Substances; D010455:Peptides; D015291:Transforming Growth Factors; D010447:Peptide Hydrolases; D005341:Fibrinolysin; D002402:Cathepsin D